Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

AstraZeneca: China is Important Source for Innovative Drug Development

publication date: May 22, 2024

During an Investors’ Day, AstraZeneca’s CEO Pascal Soriot pointed towards China as an important contributor for its plans to increase revenue by 75% to $80 billion in 2030. He said innovation in China has “exploded,” and continued with praise for the country’s expertise in cell therapies: “Cell therapy in China has a very specific aspect to it, which is in the early phase of clinical development you can move much faster than anywhere else in the world.” He continued, “We have the ability to leverage that specificity, which is mostly regulatory-driven, but also the way people operate, that will help us save time and be much faster." More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital